Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Digestive System Neoplasms × anlotinib × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2 NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1 Digestive System Neoplasms 1

Interventions

repotrectinib 1 pralsetinib 1 lutetium Lu 177 dotatate 1 copper dotatate CU-64 1 anlotinib 1 Sunitinib 1 Lutetium-177 1 Lutetium 1 E-7386 1 Cholecystectomy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04207463 2020-06-17

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown

EndocrineGastrointestinalNET

Digestive System Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡